BNTX logo

BNTX BioNTech SE

NASDAQ Global Select · Biotechnology · Healthcare

$81.38
-1.88 (-2.26%)

BioNTech SE is a biotechnology firm dedicated to the research, development, and marketing of immunotherapies for oncology and a spectrum of infectious diseases. Its diverse product pipeline features several FixVac candidates, including BNT111, currently undergoing Phase II clinical trials for advanced melanoma; BNT112, in Phase I/IIa development for prostate cancer; BNT113, progressing through Pha…

Price

No data yet.

Social Signal Score

43
5d
—
30d
41
4 mentions
—
60d
43
15 mentions
—
90d
44
24 mentions
—
news: 24

Analyst Ratings

24 analysts
Buyconsensus
Strong Buy 0Buy 20Hold 4Sell 0Strong Sell 0
Avg price target$118.57+45.7%
Low $96Median $114High $140
Current Consensus

Revenue

$1.29B+5841.29%
$20.40M$2.14B$4.26B$6.37B
Mar 2018Sep 2026

Analyst Estimates

FY2025
$-3.51
$-4.24–$-3.06
12 analysts
FY2026
$-5.63
$-6.11–$-5.15
8 analysts
FY2027
$-5.46
$-5.57–$-5.33
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Ugur Sahin
Sector
Healthcare
Industry
Biotechnology
Employees
7,807
Beta
1.33
Country
DE
Piotroski score
4 / 9 (Middling)
Altman Z-score
6.45
www.biontech.com/de/de/home.html